Salipro Biotech AB is a pioneering brand focused on enhancing drug development. With a team of experts who have worked extensively on unstable membrane proteins, Salipro® has revolutionized the field. Traditional methods for stabilizing membrane proteins often proved laborious and resource-intensive.

Recognizing the need for a more efficient approach, Salipro Biotech developed their innovative Salipro® platform. Since its establishment in 2016, Salipro® has empowered researchers across the globe, enabling them to work with challenging drug targets. This platform has unlocked the potential for making previously undruggable targets druggable.

Now, researchers can take a drug target from the cell and prepare it for the development of small molecules, therapeutic peptides, antibodies, and more. Salipro Biotech aims to drive meaningful change and spearhead the development of novel therapies. Their dedicated team, led by CEO Jens Frauenfeld and CSO Robin Löving, is committed to pushing boundaries and making a real difference in the pharmaceutical industry.

With their expertise and cutting-edge technology, Salipro Biotech is poised to shape the future of drug development